Will Delays in Treatment Jeopardize the Population Benefit From Extending the Time Window for Stroke Thrombolysis? | Zendy

Martin Pitt | Zendy; Thomas Monks | Zendy; Paritosh Agarwal | Zendy; David Worthington | Zendy; Gary A. Ford | Zendy; Kennedy R. Lees | Zendy; Ken Stein | Zendy; Martin James | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Will Delays in Treatment Jeopardize the Population Benefit From Extending the Time Window for Stroke Thrombolysis?

Author(s) -

Martin Pitt,

Thomas Monks,

Paritosh Agarwal,

David Worthington,

Gary A. Ford,

Kennedy R. Lees,

Ken Stein,

Martin James

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.638650

Subject(s) - medicine , thrombolysis , population , tissue plasminogen activator , stroke (engine) , censoring (clinical trials) , arrival time , recombinant tissue plasminogen activator , dosing , emergency medicine , surgery , ischemic stroke , ischemia , mechanical engineering , environmental health , pathology , myocardial infarction , transport engineering , modified rankin scale , engineering

Pooled analyses show benefits of intravenous alteplase (recombinant tissue-type plasminogen activator) treatment for acute ischemic stroke up to 4.5 hours after onset despite marketing approval for up to 3 hours. However, the benefit from thrombolysis is critically time-dependent and if extending the time window reduces treatment urgency, this could reduce the population benefit from any extension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research